Savara Secures $75M Debt Facility Tied to MOLBREEVI Approval
Event summary
- Savara amended its loan agreement with Hercules Capital, securing up to an additional $75 million in debt funding.
- The additional funding becomes available upon FDA approval of Savara’s investigational therapy, MOLBREEVI, for autoimmune pulmonary alveolar proteinosis (autoimmune PAP).
- Savara estimates the autoimmune PAP market to be approximately 50% larger than previously thought.
- The amended agreement maintains existing loan maturity and interest-only period, with no warrants attached.
- Savara anticipates having ~$150 million in non-dilutive capital upon MOLBREEVI approval, combining the Hercules facility and a royalty financing from RTW.
The big picture
Savara’s securing of this substantial debt facility underscores the increasing investor interest in therapies targeting rare diseases, which often command premium pricing. The financing structure, contingent on FDA approval, is common in the biopharmaceutical sector but introduces a significant execution risk. With ~$2.3B AUM, Hercules Capital continues to be a key player in funding clinical-stage biopharma companies, and this deal signals confidence in Savara’s potential.
What we're watching
- Regulatory Headwinds
- The timing of the FDA’s Priority Review decision will be critical; a delay could significantly impact Savara’s financial projections and debt repayment schedule.
- Execution Risk
- Savara’s ability to effectively execute launch activities and capture the estimated market share will determine the return on this newly secured capital.
- Financial Leverage
- The company's ability to manage its increased debt load, particularly if MOLBREEVI’s commercial performance falls short of expectations, warrants close monitoring.
Related topics